Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RST020
MIFTS: 23

Restless Legs Syndrome 6

Categories: Rare diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Restless Legs Syndrome 6

About this section

MalaCards integrated aliases for Restless Legs Syndrome 6:

Name: Restless Legs Syndrome 6 57 75
Restless Legs Syndrome, Susceptibility to, 6 57 53 13
Rls6 57 53 75
Periodic Limb Movements in Sleep 57 53

Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 611185
MedGen 42 C1970020
MeSH 44 D012148
Sources

Summaries for Restless Legs Syndrome 6

About this section
OMIM : 57 Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs during periods of rest. The majority of patients with RLS also have periodic limb movements in sleep, which are characterized by involuntary, highly stereotypical, regularly occurring limb movements that occur during sleep. Limb movements during sleep are more common in otherwise asymptomatic family members of patients with RLS compared to the general population (Stefansson et al., 2007). Thus, periodic limb movements during sleep may serve as an endophenotype for RLS. However, not all patients with RLS have limb movements during sleep, and the majority of individuals with limb movements during sleep do not have waking symptoms of RLS (Winkelman, 2007). For additional information and a discussion of genetic heterogeneity of RLS, see RLS1 (102300). (611185)

MalaCards based summary : Restless Legs Syndrome 6, also known as restless legs syndrome, susceptibility to, 6, is related to restless legs syndrome and periodic limb movement disorder. An important gene associated with Restless Legs Syndrome 6 is RLS6 (Restless Legs Syndrome, Susceptibility To, 6). The drugs Dopamine and Pramipexole have been mentioned in the context of this disorder. Affiliated tissues include skin.

UniProtKB/Swiss-Prot : 75 Restless legs syndrome 6: A neurologic sleep/wake disorder characterized by uncomfortable and unpleasant sensations in the legs that appear at rest, usually at night, inducing an irresistible desire to move the legs. The disorder results in nocturnal insomnia and chronic sleep deprivation. The majority of patients also have periodic limb movements in sleep, which are characterized by involuntary, highly stereotypical, regularly occurring limb movements that occur during sleep.

Sources

Related Diseases for Restless Legs Syndrome 6

About this section

Diseases related to Restless Legs Syndrome 6 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 restless legs syndrome 30.9 BTBD9 RLS6
2 periodic limb movement disorder 11.3
3 restless legs syndrome 7 11.0

Sources

Symptoms & Phenotypes for Restless Legs Syndrome 6

About this section

Clinical features from OMIM:

611185
Sources

Drugs & Therapeutics for Restless Legs Syndrome 6

About this section

Drugs for Restless Legs Syndrome 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2 104632-26-0 59868 119570
3
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
4
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-20-8, 91374-21-9 5095 497540
5
Iron Approved Phase 4 7439-89-6 23925
6 tannic acid Approved, Nutraceutical Phase 4,Phase 3
7 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Dopamine agonists Phase 4,Phase 3,Phase 2
9 N 0437 Phase 4,Phase 3,Phase 2
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Antioxidants Phase 4,Phase 3,Phase 2
12 Antiparkinson Agents Phase 4,Phase 3,Phase 2
13 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Arginine Vasopressin Phase 4
15 Coagulants Phase 4
16 Deamino Arginine Vasopressin Phase 4
17 Hemostatics Phase 4
18 Natriuretic Agents Phase 4
19 Vasopressins Phase 4
20 Autonomic Agents Phase 4,Not Applicable
21 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
22 Ferric Compounds Phase 4
23 Hematinics Phase 4
24 Micronutrients Phase 4
25 Trace Elements Phase 4
26 arginine Nutraceutical Phase 4
27
Lisuride Approved, Investigational Phase 3 18016-80-3 28864
28
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
29
Cabergoline Approved Phase 3 81409-90-7 54746
30
Levodopa Approved Phase 3 59-92-7 6047
31 Serotonin Agents Phase 3
32 Analgesics Phase 3
33 Anti-Anxiety Agents Phase 3
34 Anticonvulsants Phase 3
35 calcium channel blockers Phase 3
36 Calcium, Dietary Phase 3
37 Central Nervous System Depressants Phase 3
38 Psychotropic Drugs Phase 3
39 Tranquilizing Agents Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
2 Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT00472199 Phase 4 Pramipexole;Placebo
3 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
4 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome Completed NCT00373542 Phase 4 ropinirole CR-RLS
5 A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS Completed NCT00349531 Phase 4 Pramipexole
6 Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
7 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4 Desmopressin lyophilisate (Melt)
8 Switching From Oral Dopamine Agonists to Rotigotine Completed NCT01976871 Phase 4 Rotigotine
9 Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
10 Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT01569464 Phase 3 Rotigotine
11 Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00367822 Phase 3 Lisuride;Ropinirole;Placebo
12 Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects Completed NCT00498108 Phase 3 Rotigotine
13 Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS) Completed NCT00654498 Phase 3 Pramipexole;Placebo
14 A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis Completed NCT01537042 Phase 3 Rotigotine;Placebo
15 Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed NCT00136045 Phase 3 Rotigotine
16 Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
17 Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance Completed NCT00991276 Phase 3 pregabalin;placebo;pramipexole
18 A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS Completed NCT00625547 Phase 3 cabergoline;levodopa
19 A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS Completed NCT00627003 Phase 3 Cabergoline
20 Rotigotine Restless Legs Syndrome Dose Finding Trial Completed NCT00243217 Phase 2 SPM 936
21 Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome Completed NCT00152997 Phase 2 Pramipexole 0.125 mg tablets;Pramipexole 0.125 mg tablets Placebo
22 Verification of Computerized Sleep-wake Analysis in Sleep Disorders Unknown status NCT02412527
23 Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS) Completed NCT00887289
24 Dopamine Transporter Density Profiles in Patients With Periodic Limb Movements Completed NCT01365364 Not Applicable
25 Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise Completed NCT01113710 Neupro®
26 Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS) Completed NCT02248142 Pramipexole
27 The Link Between Clinical and Physiological Sleep Data and Health-related Outcomes Recruiting NCT03383354

Search NIH Clinical Center for Restless Legs Syndrome 6

Sources

Genetic Tests for Restless Legs Syndrome 6

About this section
Sources

Anatomical Context for Restless Legs Syndrome 6

About this section

MalaCards organs/tissues related to Restless Legs Syndrome 6:

41
Skin
Sources

Publications for Restless Legs Syndrome 6

About this section

Articles related to Restless Legs Syndrome 6:

# Title Authors Year
1
The Role of Iron in Pediatric Restless Legs Syndrome and Periodic Limb Movements in Sleep. ( 28837991 )
2017
2
Evaluation of Periodic Limb Movements in Sleep and Iron Status in Children With Autism. ( 26231264 )
2015
3
The validity of the PAM-RL device for evaluating periodic limb movements in sleep and an investigation on night-to-night variability of periodic limb movements during sleep in patients with restless legs syndrome or periodic limb movement disorder using this system. ( 24269130 )
2014
4
Periodic limb movements in sleep contribute to further cardiac structure abnormalities in hemodialysis patients with restless legs syndrome. ( 23372468 )
2013
5
L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children. ( 21463967 )
2011
6
Remission of severe restless legs syndrome and periodic limb movements in sleep after bilateral excision of multiple foot neuromas: a case report. ( 20849622 )
2010
7
A genetic risk factor for periodic limb movements in sleep. ( 18216367 )
2008
8
Periodic limb movements in sleep and periodic limb movement disorder. ( 17235435 )
2007
9
A genetic risk factor for periodic limb movements in sleep. ( 17634447 )
2007
Sources

Variations for Restless Legs Syndrome 6

About this section
Sources

Expression for Restless Legs Syndrome 6

About this section
Search GEO for disease gene expression data for Restless Legs Syndrome 6.
Sources

Pathways for Restless Legs Syndrome 6

About this section
Sources

GO Terms for Restless Legs Syndrome 6

About this section
Sources

Sources for Restless Legs Syndrome 6

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....